What Treatment Should We Dare in Patients With In-Stent Restenosis?

Affiliations

¹ Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: kastrati@dhm.mhn.de.
² Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
³ Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.

Free article

Editorial

Adnan Kastrati et al. JACC Cardiovasc Interv. 2018.

Free article

. 2018 Feb 12;11(3):284-286.

doi: 10.1016/j.jcin.2017.11.024.

¹ Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: kastrati@dhm.mhn.de.
² Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
³ Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.

No abstract available

Keywords: bare-metal stent(s); drug-eluting balloon; drug-eluting stent(s); restenosis.

Comment on

A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
Baan J Jr, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, de Winter RJ, Koch KT, Sjauw KD, Beijk MA, Vis MM, Wykrzykowska JJ, Piek JJ, Tijssen JGP, Henriques JPS. Baan J Jr, et al. JACC Cardiovasc Interv. 2018 Feb 12;11(3):275-283. doi: 10.1016/j.jcin.2017.10.024. Epub 2017 Nov 7. JACC Cardiovasc Interv. 2018. PMID: 29413242 Clinical Trial.